INSIGHTEC, founded in 1999, develops and distributes the Exablate platform which provides non-invasive treatments for a variety of oncology and gynecology indications. The Exablate platform uses revolutionary MRgFUS technology which combines high intensity focused ultrasound guided by Magnetic Resonance Imaging (MRI). Focused ultrasound waves, guided by magnetic resonance imaging are used to safely ablate targeted tissue, ensuring a high rate of effectiveness with minimal side effects. INSIGHTEC is continuously investing and expanding its current and investigational applications, ranging from functional neurosurgery to oncology and gynecology. With over 13,000 Exablate treatments to date, MRgFUS technology is embraced by world renowned physicians in more than 120 medical facilities. The company has received numerous innovation awards - among them are The Wall Street Journal and TIME magazine. INSIGHTEC is privately held by GE Healthcare, Elbit Imaging, York Capital Management, GEOC Hengtong Investment Limited Partnership and MediTech Advisors.

INSIGHTEC: The vision of non-invasive surgery

Kobi Vortman, the visionary behind INSIGHTEC's focused ultrasound platform, explains how the non-invasive technology allows treated patients to quickly return to their lives.

INSIGHTEC’s vision:


INSIGHTEC was started by engineers and PhD's from the world renowned Technion - Institute of Technology, who were and still are passionate about combining several scientific disciplines to develop a breakthrough medical technology that will make a real impact on the lives of millions of people, globally. INSIGHTEC is passionate about discovering new technologies, combining knowledge from many different disciplines and bringing our technology to a whole new level. INSIGHTEC values innovation, precision and operational efficiency and we thrive when we reach excellence in both science and technology. As part of our innovative, long term vision, we are constantly looking into the future - expanding our treatment portfolio with treatment of brain tumors, prostate cancer and liver tumors. Over the years, we have assembled a team of professionals who are the best in their field, whether it’s medicine, engineering, business, marketing, or software development - people who share the INSIGHTEC dream of providing better healthcare and exceptional clinical outcomes.

Awards & Recognitions


CEO World Award

INSIGHTEC WINS GOLD FOR: First MRI-guided focused ultrasound platform FDA-approved to treat essential tremor. For more information: CLICK HERE

Forbes: Voted One of the 10 Innovative Companies to Watch for In 2016

The INSIGHTEC Exablate procedure uses guided ultrasound and MRI to enable doctors to treat bone metastasis and symptomatic uterine fibroids without performing any surgery. If widely adopted, the technology could reduce the need for surgery for many patients around the globe.

INSIGHTEC was included in the World Medical Innovation Forum’s “Disruptive Dozen” list

This prestigious list recognizes the 12 emerging technologies with the potential to revolutionize neurological and psychiatric care over the next decade. Specifically, INSIGHTEC was recognized for its Neurology solution, combining transcranial MRI-guided focused ultrasound and focused ultrasound with microbubbles that allow physicians to target tissues deep within the body through the use of sound waves, as opposed to incisions and radiation. Focused ultrasound has the ability to revolutionize the treatment of conditions such as brain cancer and Alzheimer’s through its potential for greater precision and quicker patient recovery. 

TIME magazine has named MR guided Focused Ultrasound (Exablate MRgFUS) as one of the 50 best inventions of the year.

Time Magazine Award - The report, which appeared in the magazine’s Novmber 28, 2011 “invention” issue, states: “Magnetic-resonance-imaging (MRI) and ultrasound technologies are each remarkable in their own right, but combine them and you get something life-changing. A technique called focused ultrasound uses MRI pictures to guide multiple beams of acoustic energy into concentrated hot spot deep inside the body to heat and melt away tumors or other growths like uterine fibroids. A version of the device is being tested to tweak brain regions to relieve pain and even tremors associated with Parkinson’s.”

The World Economic Forum has selected INSIGHTEC as one of its Technology Pioneers for 2008

Technology Pioneers are companies developing and applying technologies deemed highly transformational and innovative in the areas of energy, biotechnology and health and information technology.
The World Economic Forum appointed a panel of leading technology experts to select finalists from a pool of 273 nominees. INSIGHTEC’s vision is to develop next generation, non-invasive, outpatient operating room that minimizes trauma, morbidity and recovery time. The company’s Exablate® 2000 is the world’s first and only non-invasive surgery system to combine focused ultrasound and magnetic resonance imaging.

Red Herring 100 Europe 2007 Award

Red Herring magazine has named INSIGHTEC to its Red Herring 100 Europe 2007 list of the top privately-held technology companies in Europe, the Middle East and Africa (EMEA). Red Herring lists of top private companies are an important part of the company’s tradition of identifying new and innovative technology companies and entrepreneurs. Companies like Google, eBay and Skype were spotted in their early days by Red Herring editors, and touted as leaders that would change the way we live and work. Red Herring editorial staff rigorously evaluates entrepreneurial companies in a careful analysis of financial data and subjective criteria, including quality of management, execution of strategy, and dedication to research and development.

INSIGHTEC was the winner of Frost and Sullivan’s 2005 Technical Innovation Award

INSIGHTEC was the winner of Frost and Sullivan’s 2005 Technical Innovation Award in the field of non-invasive medical devices for outstanding industry achievement. Frost & Sullivan, the international growth consulting firm, recognized INSIGHTEC as its Exablate® 2000 was the first U.S. Food and Drug Administration (FDA) approved Magnetic Resonance-guided Focused Ultrasound (Exablate MRgFUS) technology for the non-invasive treatment of uterine fibroids.

INSIGHTEC’s Exablate Neuro was awarded the Wall St. Journal's Technology Innovation Award - Bronze Winner!

The award recognizes technological breakthroughs by individuals, companies and organizations around the world in a wide range of areas, including medicine, software, hardware, the Internet, wireless and broadcasting. “Through these awards, The Wall Street Journal seeks to recognize innovation—and each of these winners embodies the creative thinking that enabled them to rise the top of their respective industries,” said Karen Elliott House, publisher, The Wall Street Journal, and senior vice president, Dow Jones & Company. “We also believe that in today’s business environment, it has never been more important to discover and nurture new ideas".

Please fill in the following details and we will get in touch with you. (* Required)

agreement Error

Thank You!

Thank you for contacting us! We will get back to you shortly.

Thank You!

This site is brought to you by INSIGHTEC, © 2018 Insightec Ltd. All rights reserved.

NGSoft logo